Verastem Oncology Reports Third-Quarter 2026 Financial Results
Verastem Oncology reported financial results for the quarter ended September 30, 2026. The supplied body is truncated and provides no results figures.
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the third quarter ended September 30, 2026, and highlighted recent business progress.“During the third quarter, w…